Conservatism, Consumer Choice, and the Food and Drug Administration during the Reagan Era

Regular price €62.99
Quantity:
In stock with our UK publisher. 14-28 days
Delivery/Collection within 10-20 working days
14 days return policy Shipping & Delivery
A01=Lucas Richert
Age Group_Uncategorized
Age Group_Uncategorized
Author_Lucas Richert
automatic-update
Category1=Non-Fiction
Category=JBF
Category=JFFU
Category=JPQB
Category=KND
Category=KNDF
Category=KNDP
Conservatism
COP=United States
Delivery_Delivery within 10-20 working days
Drugs
eq_bestseller
eq_business-finance-law
eq_isMigrated=2
eq_nobargain
eq_non-fiction
eq_society-politics
History of Medicine
Language_English
PA=Available
Price_€50 to €100
PS=Active
Public Policy
Ronald Reagan
softlaunch

Product details

  • ISBN 9780739194645
  • Weight: 349g
  • Dimensions: 152 x 228mm
  • Publication Date: 18 Apr 2016
  • Publisher: Bloomsbury Publishing Plc
  • Publication City/Country: US
  • Product Form: Paperback
  • Language: English
Secure checkout Fast Shipping Easy returns

In the last quarter of the 20th century, politicians in Washington, as well as interest groups, regulatory policy makers, and drug industry leaders were forced to confront the hot-button issue of pharmaceutical regulation. The struggle always centered on product innovation, consumer protection, and choice in the free market. As the American economy stuttered in the late 1970s, the stakes were extremely high for the powerful drug industry and the American public. At the center of this drama was the Food and Drug Administration, which was censured from both the left and right of the political spectrum for being too strict and too lenient in the application of its regulatory powers.

Lucas Richert explores the FDA, drugs, and politics in the context of the watershed Reagan era, a period when the rhetoric of limited government, reduced regulation, and enhanced cooperation between businesses and U.S. regulatory agencies was on the ascent.As he investigates the controversies surrounding Laetrile, Reye’s Syndrome, Oraflex, patient package inserts, diet pills, and HIV/AIDS drugs, Richert argues that the practical application of conservative economic principles to the American drug industry was A Prescription for Scandal.

Lucas Richert is a postdoctoral fellow at the University of Saskatchewan.

More from this author